Interim Report 1, 2007

The world leader in innovative evidence-based esthetic dental solutions

Disclaimer:This presentation contains forward-looking statements that are subject to various risk and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.

Nobel Biocare in 60 Seconds

> Number 1 position globally and in all regions

> SWX market cap of CHF 11.5 bn> >2100 employees worldwide> The one-stop shop for restorative

esthetic dentistry> Leading in science, training and

education, innovation> Our focus is the patient and the

dental professional our customer

The world leader in innovative evidence-based esthetic dental solutions

Profit Lines of Income Statement Show All New Record Levels

Profit for the periodEBIT marginEBITGross marginGross profitRevenue

Operating Cash Flow

*Revenue growth in local currencies

Q1 2007 EUR

21.026.9%

43.9

84.2%137.6163.5

1.76Basic earnings p. share10.7

26.1%37.2

83.7%119.5142.7

Q1 2006 EUR

1.48

34.0%

+96%+80bp+18%

+50bp+ 15%+20%*

Growth

+19%

-55.6 48.5 +15%

34.0%

Profit margin

Strong Performance track record since 2001

> More than doubled revenues in five years

FY 2001: Euro 288.2 Mio. FY 2006: Euro 600.6 Mio.

> Outgrowing the market since 2003

Revenue Growth (%)

EBIT margin 2001 - 2006

10%

15%

20%

25%

2002 2003 2004 2005 2006 Q107

19.7%

15%

20%

25%

30%

35%

40%

2002 2003 2004 2005 2006 Q107

20.3%

12.4%

> Highest EBIT margin in the dental industry

FY 2001: 13.5 % FY 2006: 34.0 % Q1 2007: 34.0 %

34.0 %

Maintained Record EBIT Margin Despite Significant Higher Social Charges

ReportedEBIT

marginQ1 06

34.0%+0.5%

Grossmargin

Operatingexpenses

-2.4%

EBITmarginQ1 07

34.0%

ReportedEBIT

marginQ1 07

36.4%

Socialcharges

+1.9%

Record Net Profit for the quarter

Net ProfitQ1 06

37.2

GrossProfit

Operatingexpenses

Taxes

18.1

in EUR million

-7.0

EUR 7.1 millioncontribution

to EBIT

-4.0

SocialCharges

1.7

Financialresult

-2.1

43.9

Net ProfitQ1 07

Balance Sheet and Cash Flow at a Glance

10.721.0Cash Flow from operations

72%76%Equity/Asset ratio1.83.5in percent of revenue2.65.77.512.8in percent of revenue

25.325.2in percent of revenue*144.3164.5Current receivables

4.94.5in percent of revenue*27.729.7Inventories

31/03/200631/03/2007MEUR

Capital Expenditures

* annualized

Strong Operational Cash Flow – doubled vs Q1 2007

Cash available

Jan 1

130.9

Operatingactivities

Investingactivites

OtherFinancingActivities /Currency

impact

21.0

in EUR million

-5.7

0.3

Interest Share buyback

-7.5

9.1 148.1

Cash availableMar 31

Operational Highlights – Q1 2007

Employees

1000

1250

1500

1750

2000

2250

2001 2002 2003 2004 2005 2006 Q107

> 115 new employees in Q1 2007> 50% new employees since end of

2001

2001: 1328 employees2006: 1993 employees

2 108

Global workforce expansion

Trainer and Educator of the Industry

> Q1 2007 - 75,000 participants in the Group’s training programs,

> +22% compared to Q1 2006.

0

50

100

150

200

250

300

350

400

2002 2003 2004 2005 2006 Q107 Target2007

Number of trained (000)

1 328

Operational Highlights – Q1 2007

> New state-of-the-art Europeandistribution center opened in Venlo, the Netherlands.

> ISO 13485:2003 certified

Distribution Center, Venlo (NL)

> Shop Online orders for standard components increased by more than 50% compared to Q1 2006.

> Together with Procera, 20% of all orders are coming through Shop Online.

Shop Online

State-of-the-art Infrastructure

You decide – we provide

Operational Highlights – Q1 2007

> FY 2006 1,336 editorial articles> Q1 2007 312 editorial articles,

26% more than Q1 2006> NobelSmile patient campaign in 34

countries

Editorial articles

50

0

250

500

750

1000

1250

1500

2003 2004 2005 2006 Q1 2007

312297

Reduce lack of Information

World Market Leader in C&B&I

> No. 1 position globally> No. 1 position in North America,

Europe, Asia and Rest of the World

> World market leader in C&B&I> Root-to-tooth solutions

Market Shares in Dental Implant MarketSource: Company Reports and Nobel Biocare estimates

37% Nobel Biocare

22%Straumann

11% Biomet/3i

9% Zimmer

6% Dentsply

15% Others

Leader in All Regions

Q1 2007 Revenues by Region (MEUR) Revenue Growth by Region (%) Q107 vs. Q106

Europe

North AmericaAsia/Pacific

Rest of World

9.0

79.1

53.322.1

0

10

20

30

40

50

60

NorthAmerica

Europe Asia/Pacific ROW

24%

31% 33%

12%

48%

33%14%

5%

10%

18%

45%49%

Growing the Market

Source: WHO

6-10% of the Worldwide Population is FullyEdentulous

USA 33 % >65 years 20.000.000Brasil 74 % >65 years 8.800.000United Kingdom (one jaw) 30 % >55 years 3.800.000Germany 25 % >65 years 3.000.000Spain 37 % >65 years 2.400.000 Canada 58 % >65 years 2.300.000 Italy 19 % >65 years 2.200.000France 16 % >65 years 1.600.000Netherland 64 % >65 years 1.500.000Portugal 70 % >65 years 1.400.000Belgium 41 % >65 years 740.000Switzerland 27 % >65 years 250.000Sweden 13 % >65 years 200.000

Nearly 50 million fully edentulous people in the western world

Source: WHO

China 11 % >65 years 14.500.000India 19 % >65 years 10.400.000Japan 20 % >65 years 4.000.000Indonesia 24 % >65 years 3.200.000Vietnam 23 % >65 years 1.100.000Southkorea 22 % >65 years 950.000Thailand 16 % >65 years 820.000Malaysia 57 % >65 years 690.000Hong Kong 20 % >65 years 160.000

... and another 36 million people in Asia

Huge Untapped Worldwide Market Potential to Serve Fully Edentulous People

Source: WHO and Nobel Biocare estimates

Estimated € 50 bn Market Potential in North America, Europe, Japan

Sustainable Future Growth Potential in the Tooth Replacement Market

>240 million people missing one tooth or more (North America, Europe, Japan)~ 60 million patients treated conventionally

~ 8 million patients treated with dental implants

> Market penetration in North America, Europe and Japan still around 3%

> € ~ 50 bn Market Potential North America, Europe, Japan

> China, India, Russia, Latin America largely untapped

> Sustainable industry growth for coming years of 18 – 20% p.a.

3%

19%

78%

Nobel Biocare Grows Faster than the Market

10

15

20

25

30

2001 2002 2003 2004 2005 2006

Revenue Growth Rates 2001-2006 in %

Nobel BiocareMarket (MRG)*

Source: MRG and Nobel Biocare estimates

* Based on MRG’s overall market - Nobel Biocare excluded

> Above market growth in every region

> Strong growth in emerging markets

Limitations for Growth

Lack of informationLack of educationEducation in Universities

Dental professionalLack of informationFear of PainAffordabilityTimeAllergiesBone quality & quantity

Patient

… and Nobel Biocare has Unique Solutions for all

Lack of information

Lack of education

Education in universities

Dental professional

Lack of information

Fear of pain

Affordability

Time

Allergies

Bone quality & quantity

PatientNobelSmile Awareness Campaign

Graftless Proc. / Minimal Invasive

Overdenture / All-on-4 /Teeth-in-an-hour

Immediate Function / NobelGuide

Metal Free Solution (ZiUnite)

Bone Inductive Implant (BMP-2)

World Conference / World Tour

Training & Education / World Tour

University undergraduate programs

NobelSmile Campaign & Find a doctor

Dental professional

Patient

Lim

itatio

ns fo

r Gro

wth

Gro

win

g th

e M

arke

t

Uni

que

Nob

el B

ioca

re

Solu

tions

Trendsetter of the Industry with the Highest Number of High Impact Introductions

> 1965 First modern dental implant > 1988 Inventor of CAD/CAM in

dentistry> 1995 Inventor of modern ceramic

materials in dentistry> 1997 Replace tapered implant> 2002 Immediate Function> 2003 NobelPerfect> 2004 NobelDirect

NobelRondoPersonalized abutments for Straumann, 3i, Zimmer and Lifecore

> 2005 NobelGuide Teeth-in-an-HourGroovyNobelSpeedy / ShortyTiUnite all the way up

> 2006 Procera Bridge AluminaProcera Laminate

Trendsetter of the Industry with the Highest Number of High Impact Introductions - 2007

> NobelRondo PressProcera Implant Bridge ZirconiaProcera Bridge Zirconia for teeth (for up to 14 units)

> Platform shiftingQuickTemp Abutment conicalMaxillofacial ConceptNobelActiveCurvy Abutment

Overcome Fear of Pain – Immediate Function

> TiUnite® maintains initial stability > TiUnite®: Biomaterial with proven

osteoconductivity> TiUnite®: Carrier for bioactive

agents. No grafting and no membranes needed

> 75 Studies* on Immediate Function™

> 5 year data with excellent results

Only Surface with a Proven Clinical Protocol for Immediate Function

6000

6300

6600

6900

0 1 Week 1 Month 2 Months 3 Months 6 Months

TiUnite Machined Surface

*Source: Medline

Results of resonance frequency analyses show that the high initial stability achieved with TiUnite® is maintained at a high level throughout the healing phase. Glauser et al. Applied OsseointegrationResearch 2001;2:27-29.0

Reduce Limitations of Time

> NobelGuide™ a system for complete oral rehabilitation

> FDA approved since 2004> One surgical visit required with

NobelGuide™> NobelGuide™ is a proven

concept with full flexibility

3 - 4 Visitswith NobelGuide™

10 VisitsConvential Approach

Treatment PlanningTreatment PlanningSurgical Procedure Surgical Procedure

Relining

Remove Stitches

Abutment Connection

Temporary Prosthetic Solution

Temporary / Final Prosthetic Solution

Soft-tissue Control

Impression

Try in of Prosthesis

Final ProstheticSolutions

Final ProstheticSolutions

Reduce Limitation Lack of Patient Informationwww.nobelsmile.com

> NobelSmile Campaign in 34 countries and 20 languages with patient feature:

> Search for a doctor> NobelSmile website: 250,000

visitors in 2006> Direct patient dialogue to inform on

today’s treatment solutions> National patient information events > Information packages for patients> Collaborations with spokespersons

Patient Seminar on World Tour in Dresden 2006

Previous Nobel Biocare World Conferences

> 20032,600 participants62 speakers84 presentations

> 2005

6,000 participants

176 speakers

7 live sessions

40 translators

74 different nationalities attending

0

2000

4000

6000

8000

10000

12000

2003 2005

Nobel Biocare World Conference 2007

> 200710, 000 participants340 speakers from 34 countries35 live sessions2,143 presentations313 scientific posters

91 nationalities attending0

2000

4000

6000

8000

10000

12000

2003 2005 2007

All Nobel Biocare Solutions are Evidence Based

> Over 1800 peer reviewed scientific publications

> Strongest scientific database in the industry

> More than 50% of all scientific studies come from Nobel Biocare

> >600 renowned scientists and dental practitioners

> All products launched globally with FDA approval

> 60 university research collaborations worldwide

0

20

40

60

80

100

NB ITI 3i Astra Others

MedLine database, April 2007

Nobel Biocare has more Studies on Immediate Function than the other Companies Together

Nobel Biocare’s Strong Commitment to Social Responsibility

> SOS-Children’s Villages, Kiev, Ukraine

> P-I Brånemark Institute, Bauru, Brazil – Donation run institute for treatment for needy patients requiring osseointegratedreconstructions

> iADH - International organization for the treatment of disabled patients

> Cleft-Children, organization for the treatment of children with severe cleft lip and palate

P-I BrånemarkInstitute, Bauru

Outlook 2007

EBIT margin 34-35%23-25%Revenue Growth*

*in local currency